Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Reactions
Skin
Diaphoresis (>1%)
Edema (1–10%)
Exanthems
(1998): Hernandez-Cano N+, Lancet 352, 202 (generalized)
(1998): Rosen R (following PUVA) (from Internet) (observation)
Facial edema (>1%)
Lichenoid eruption
(1993): Shelley WB+, Cutis 52, 88 (observation)
Peripheral edema (5.5%)
Phototoxicity
(1993): Shelley WB+, Cutis 52, 259 (observation)
Pruritus (>1%)
(1998): Hernandez-Cano N+, Lancet 352, 202
Rash (sic) (>1%)
Mucosal
Xerostomia (1–10%)
Other
Anaphylactoid reactions/Anaphylaxis
Myalgia/Myositis/Myopathy/Myotoxicity (>1%)
TERBINAFINE
Trade name: Lamisil (Novartis)
Indications: Fungal infections of the skin and nails
Category: Antimycobacterial
Half-life: 22–26 hours
Clinically important, potentially hazardous interactions
with: carbamazepine
Reactions
Skin
Acute generalized exanthematous pustulosis (AGEP)
(2006): Bajaj V+, Acta Derm Venereol 86(5), 448
(2005): Beltraminelli HS+, Br J Dermatol 152(4), 780
(2005): Greco M+, Eur J Dermatol 15(2), 116
(2003): Lombardo M+, JAmAcadDermatol49(1), 158
(2003): Saissi EH+, Ann Dermatol Venereol 130(6-7), 612
(2003): Taberner R+, Eur J Dermatol 13(3), 313
(2001): Rogalski C+, Hautarzt 52(5), 444
(2000): Hall AP+, Australas J Dermatol 41, 42
(1998): Condon CA+, Br J Dermatol 138, 709
(1997): Kempinaire A+, JAmAcadDermatol37, 653
(1996): Dupin N+, Arch Dermatol 132, 1253 (2 cases)
Allergic reactions (sic) (1–10%)
(1989): Savin R, Clin Exp Dermatol 14, 116
Angioedema
(1997): Hall M+, Arch Dermatol 133, 1213
Baboon syndrome
(2001): Weiss JM+, Hautarzt 52(12), 1104
Bullous pemphigoid
(2003): Aksakal BA+, Ann Pharmacother 37(11), 1625
Dermatitis (1–10%)
Desquamation
(1995): Wachs F+, Arch Dermatol 131, 960 (passim)
Eczema (